Immune Thrombocytopenia Treatment Market: By Type, By Treatment, By Route of Administration, By Distribution Channel, and Geography

Immune Thrombocytopenia Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type (Acute, Chronic), By Treatment (Thrombopoietin Receptor Agonists, Corticosteroids, Intravenous Immunoglobulins and Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), and Region

Immune Thrombocytopenia Treatment Market size was valued at US$3,204.6 million in 2023 and is poised to grow at an 4.8% CAGR from 2024 to 2030. Thrombocytopenia is defined as an abnormally low platelet count in the blood due to the presence of any illness or ailment. Individuals with thrombocytopenia have delayed or no blood clotting. Due to the high prevalence of thrombocytopenia and growing knowledge of treatment alternatives, the global thrombocytopenia treatment market is likely to grow considerably in the near future. Furthermore, rising government support for fast-track approval to discover newer treatments for this disorder, as well as capital investments in the development of new drugs by biotechnology and pharmaceutical companies, are expected to drive growth in the thrombocytopenia treatment market over the coming years. The immune Thrombocytopenia Drug Market is being propelled by the rising prevalence of immune thrombocytopenia worldwide is a significant driver of the ITP drug market. Factors such as aging populations, improved disease awareness and diagnosis, and the growing incidence of autoimmune diseases contribute to the increasing burden of ITP, driving the demand for effective treatments.

According to the National Centre for Biotechnology Information, Immune thrombocytopenia (ITP) occurs with an incidence rate of 1.6 to 3.9 per 100,000 patient-years. The growing prevalence of ITP expands the market opportunity for pharmaceutical companies and other stakeholders involved in the development, manufacturing, and distribution of ITP drugs. A larger patient population translates to increased market potential, driving investment in R&D, marketing, and sales efforts. Pharmaceutical companies may prioritize ITP drug development initiatives to capitalize on the expanding market opportunity presented by the rising prevalence of the condition. However, high treatment costs, limited awareness in low-income regions, and adverse effects of medications are some of the restraints for the immune thrombocytopenia treatment market.

Immune Thrombocytopenia Treatment Market Key Developments:
  • In December 2021, Horizon Therapeutics Plc's board of directors and Amgen Inc.'s board of directors agreed on the terms of a cash offer for the Company by Pillartree Limited.
  • In December 2020, Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd., a subsidiary of 3SBio Inc., and Verseau Therapeutics, Inc. announced the selection of a monoclonal antibody targeting VSIG4.

Immune Thrombocytopenia Treatment Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

4.8%

Largest Market

North America

Fastest Growing Market

Asia Pacific

Global Immune Thrombocytopenia Treatment Market Dynamics

The immune thrombocytopenia treatment market is driven by a combination of factors including increasing prevalence, technological advancements, healthcare expenditure, and awareness campaigns. Novel drug delivery technologies have enhanced the administration and effectiveness of ITP medications. long-acting formulations, subcutaneous injections, and oral formulations offer improved convenience, reduced dosing frequency, and enhanced patient adherence compared to traditional intravenous therapies. These advancements in drug delivery technology have improved patient comfort and treatment compliance in ITP management.

Immune Thrombocytopenia Treatment Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$3,204.6 million

Market CAGR

4.8%

By Type

  • Acute
  • Chronic

By Treatment

  • Thrombopoietin Receptor Agonists
  • Corticosteroids
  • Intravenous Immunoglobulins
  • Others

By Route of Administration

  • Oral
  • Injectable

By Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Key Features of the Report

  • The north america poultry diagnostics market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Download Free Sample Report

Frequently Asked Questions

Immune Thrombocytopenia Treatment Market was valued at US$ 3,204.6 million in 2023 and is expected to grow at an 4.8% CAGR from 2024 to 2030.

Bristol-Myers Squibb Company, Intas Pharmaceuticals Ltd., Merck & Co. Inc., Amgen Inc., Takeda Pharmaceutical Company, and Pfizer Inc. are some of the main players currently operating in the market.

Increasing prevalence, rise in healthcare expenditure, and increase in preference towards the early stage disease diagnosis are predicted to propel the growth of the immune thrombocytopenia treatment market.

Factors such as high treatment costs, limited awareness in low-income regions, and adverse effects of medications are some of the restraints for the immune thrombocytopenia treatment market which may limit the growth of the market.

North America is expected to dominate the immune thrombocytopenia treatment market over the forecast years.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.Global Immune Thrombocytopenia Treatment Market Introduction 
2.1.Global Immune Thrombocytopenia Treatment Market  - Taxonomy
2.2.Global Immune Thrombocytopenia Treatment Market  - Definitions
2.2.1.Type
2.2.2.Treatment 
2.2.3.Route of Administration
2.2.4.Distribution Channel
2.2.5.Region
3.Global Immune Thrombocytopenia Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Immune Thrombocytopenia Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Immune Thrombocytopenia Treatment Market  By Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Acute
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Chronic
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
6.Global Immune Thrombocytopenia Treatment Market  By Treatment , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Thrombopoietin Receptor Agonists
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Corticosteroids
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Intravenous Immunoglobulins
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Others
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
7.Global Immune Thrombocytopenia Treatment Market  By Route of Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Oral
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Injectable
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
8.Global Immune Thrombocytopenia Treatment Market  By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. Hospital Pharmacy
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Online Pharmacy
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Retail Pharmacy
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
9.Global Immune Thrombocytopenia Treatment Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. North America
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.1.3. Market Opportunity Analysis 
9.2. Europe
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.2.3. Market Opportunity Analysis 
9.3. Asia Pacific (APAC)
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.3.3. Market Opportunity Analysis 
9.4. Middle East and Africa (MEA)
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.4.3. Market Opportunity Analysis 
9.5. Latin America
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.5.3. Market Opportunity Analysis 
10.North America Immune Thrombocytopenia Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Acute
10.1.2.Chronic
10.2.  Treatment  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Thrombopoietin Receptor Agonists
10.2.2.Corticosteroids
10.2.3.Intravenous Immunoglobulins
10.2.4.Others
10.3.  Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Oral
10.3.2.Injectable
10.4.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Hospital Pharmacy
10.4.2.Online Pharmacy
10.4.3.Retail Pharmacy
10.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1.United States of America (USA)
10.5.2.Canada
11.Europe Immune Thrombocytopenia Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Acute
11.1.2.Chronic
11.2.  Treatment  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Thrombopoietin Receptor Agonists
11.2.2.Corticosteroids
11.2.3.Intravenous Immunoglobulins
11.2.4.Others
11.3.  Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Oral
11.3.2.Injectable
11.4.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.Hospital Pharmacy
11.4.2.Online Pharmacy
11.4.3.Retail Pharmacy
11.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1.Germany
11.5.2.France
11.5.3.Italy
11.5.4.United Kingdom (UK)
11.5.5.Spain
12.Asia Pacific (APAC) Immune Thrombocytopenia Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Acute
12.1.2.Chronic
12.2.  Treatment  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Thrombopoietin Receptor Agonists
12.2.2.Corticosteroids
12.2.3.Intravenous Immunoglobulins
12.2.4.Others
12.3.  Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Oral
12.3.2.Injectable
12.4.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.Hospital Pharmacy
12.4.2.Online Pharmacy
12.4.3.Retail Pharmacy
12.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1.China
12.5.2.India
12.5.3.Australia and New Zealand (ANZ)
12.5.4.Japan
12.5.5.Rest of APAC
13.Middle East and Africa (MEA) Immune Thrombocytopenia Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Acute
13.1.2.Chronic
13.2.  Treatment  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Thrombopoietin Receptor Agonists
13.2.2.Corticosteroids
13.2.3.Intravenous Immunoglobulins
13.2.4.Others
13.3.  Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Oral
13.3.2.Injectable
13.4.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Hospital Pharmacy
13.4.2.Online Pharmacy
13.4.3.Retail Pharmacy
13.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1.GCC Countries
13.5.2.South Africa
13.5.3.Rest of MEA
14.Latin America Immune Thrombocytopenia Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
14.1. Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.1.1.Acute
14.1.2.Chronic
14.2.  Treatment  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.2.1.Thrombopoietin Receptor Agonists
14.2.2.Corticosteroids
14.2.3.Intravenous Immunoglobulins
14.2.4.Others
14.3.  Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.3.1.Oral
14.3.2.Injectable
14.4.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.4.1.Hospital Pharmacy
14.4.2.Online Pharmacy
14.4.3.Retail Pharmacy
14.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.5.1.Brazil
14.5.2.Mexico
14.5.3.Rest of LA
15. Competition Landscape
15.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
15.2.1.Bristol-Myers Squibb Company
15.2.2.Intas Pharmaceuticals Ltd.
15.2.3.Merck & Co. Inc.
15.2.4.Amgen Inc.
15.2.5.Pfizer Inc
15.2.6.Takeda Pharmaceutical Company
15.2.7.3SBio Inc.
15.2.8.Bayer AG
15.2.9.Boehringer Ingelheim GmbH
15.2.10.Eisai Co., Ltd.
15.2.11.Hansa Medical AB
15.2.12.Kendrion Biopharma Inc.
15.2.13.Mylan N V
15.2.14.Shionogi & Co., Ltd.
15.2.15.Hakima Pharmaceuticals Pvt Ltd
16. Research Methodology 
17. Appendix and Abbreviations 

Key Market Players

  • Bristol-Myers Squibb Company
  • Intas Pharmaceuticals Ltd.
  • Merck & Co. Inc.
  • Amgen Inc.
  • Pfizer Inc
  • Takeda Pharmaceutical Company
  • 3SBio Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Eisai Co., Ltd.
  • Hansa Medical AB
  • Kendrion Biopharma Inc.
  • Mylan N V
  • Shionogi & Co., Ltd.
  • Hakima Pharmaceuticals Pvt Ltd

Related Industry Reports